Cooperative Agreement UH2CA292129
Award Date
9/19/24
Completion Date
8/31/26
Dollars Obligated
$207K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Cooperative Agreement
Place of Performance
Scottsdale, AZ 85259, USA
Similar Awards
This $1,018,682 Cooperative Agreement award from the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) aims to construct a spatiotemporal atlas of human follicular lymphoma (FL) transformation to diffuse large B-cell lymphoma (DLBCL) and angioimmunoblastic T-cell lymphoma (AITL) evolution. The award to Yale University will leverage single-cell and spatial omics technologies to map the major cell types, mutational landscapes,...
The National Cancer Institute (NCI) awarded a $356,850 Cooperative Agreement (CFDA 93.395 - Cancer Treatment Research) to Oregon Health & Science University (OHSU) to characterize the pre-analytical steps involved in blood and bone marrow biopsy sample handling and storage/retrieval for functional assay reporting. The project aims to establish pre-analytical sample processing guidelines to enable maximal reproducibility for functional testing outcomes, including high throughput-drug...
The National Cancer Institute (NCI) awarded a $386,700 Project Grant under CFDA 93.394 "Cancer Detection and Diagnosis Research" to the Regents of the University of Minnesota. The grant, titled "Preclinical Development and Validation of Targeted Mass Spectrometry Assays for Serous Ovarian Cancer Diagnosis", will fund research to develop and validate novel multiplexed protein biomarker assays that can differentiate serous ovarian cancer patients from healthy individuals. The...
This $388,673 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of novel statistical methods to identify and evaluate predictive biomarkers for targeted cancer therapies using data from non-randomized Phase II clinical trials. The key products of this 2-year project, led by the University of Kentucky Research Foundation, include: Novel semiparametric statistical models to identify and...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $310,185 to New York University School of Medicine to conduct analytical and clinical validation of an advanced DNA methylation assay to predict recurrence in stage II melanoma patients. The project aims to refine and validate a 13-probe methylation signature that can accurately identify melanoma recurrence and mortality risk in stage II patients, using a large...
This Project Grant award from the National Cancer Institute (CFDA 93.394, Cancer Detection and Diagnosis Research) provides $386,279 to the University of Illinois to develop a microfluidic device for personalized immunotherapy screening on core needle biopsies. The goal is to create a technology that can guide oncologists in selecting the right immunotherapies for individual cancer patients. The project will involve 1) developing a core needle biopsy microfluidic cassette and protocols for...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $590,960.00 in funding to the Beckman Research Institute of the City of Hope to conduct research aimed at improving the understanding and treatment of acute myeloid leukemia (AML). The key objectives of the project are to: 1) Quantify the dynamics of leukemia potential driven by different oncogenic signals in murine models, 2) Evaluate the effects of treatment on leukemia...
The National Cancer Institute (NCI) awarded a $647,458 Cooperative Agreement under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the Massachusetts Institute of Technology (MIT) to develop a novel platform for real-time functional assessment of Acute Myeloid Leukemia (AML) minimal residual disease (MRD) therapeutic vulnerabilities. The project aims to integrate MIT's high-precision biophysical measurements, DeepCell's label-free brightfield imaging and AI-powered sorting,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $415,259 to the Rector & Visitors of the University of Virginia to conduct research on the role of long noncoding RNAs in acute myeloid leukemia (AML). The project aims to 1) determine the role of a specific regulatory RNA in primary and relapsed AML, and 2) define the mechanism underlying its deregulation in AML. This research will provide insights into how noncoding RNAs...
The National Cancer Institute (NCI) awarded a $671,072 Project Grant under CFDA 93.394 (Cancer Detection and Diagnosis Research) to the University of Washington (UW) to develop a novel ultra-miniaturized device termed "Picoliter Thin-Layer Chromatography (PTLC)" for high-throughput and sensitive analysis of lipid signaling in single cells from patient samples. This 5-year award, effective April 1, 2025, will leverage micro- and nano-fabrication techniques to create an easy-to-use,...